R&D Sector Under Threat?

To read the full article, please choose one of the following options:

The UK government's renegotiation of the Pharmaceutical Price Regulation Scheme (PPRS), which sets the prices for drugs paid by the National Health Service, is threatening the competitiveness of the country's R&D sector, claims the Association of the British Pharmaceutical Industry (ABPI).